


Barrett mucosa: histopathological assessment


A condition in which the normal stratified squamous epithelium of the oesophagus is replaced by metaplastic columnar epithelium

- ◇ The columnar-lined oesophagus was described by Norman Barrett in 1950
- ◇ Reported to be associated with gastroesophageal reflux disease in 1953




Barrett mucosa: histopathological assessment

The harsh intra-oesophageal environment of chronic GERD



Adaptation of the epithelium

Specialized intestinal metaplasia




A differentiated epithelium with crypt architecture that resembles the epithelium of the intestine

Barrett mucosa: histopathological assessment





Pearly grey-pink color of the squamous epithelium



Tongues and patches of reddish, salmon-colored mucosa

The major endoscopic landmark for the gastro-esophageal junction
The top of the gastric mucosal folds



Problems in BE


BE paradigm: Symptomatic GERD → BE → EA → EA mortality

Challenges for clinical management


Outcomes with current management

<p>a A large proportion of individuals with BE are asymptomatic</p> <p>b Nearly 50% of people develop EA without symptoms associated with GERD</p> <p>c 95% of EAs arise without prior diagnosis of BE</p> <p>d Nearly 80% of EAs arise without prior diagnosis of GERD</p> <p>e No evidence that endoscopic screening of GERD improves detection of BE prior to EA diagnosis</p>	BE not detected	Late-stage EA	High EA mortality
<p>f Vast majority of people with BE detected by endoscopy do not progress to EA; 95% die of unrelated causes</p>	BE detected	EA is rare	Low EA mortality

Pathogenesis of BE




Complex landscape of mutations in preinvasive BE stages




Ordering of mutations in preinvasive disease stages of esophageal cancer. Nat Genet 2014, Weaver et al.

WGS of BE patient




WGS of BE patient: different pathways



Neoplastic progression

- The development of EAC is a gradual process
- BE → Low-grade dysplasia → High-grade dysplasia → EAC




*Barrett's esophagus
(BE)*

*Low-grade dysplasia
(LGD)*

*High-grade dysplasia
(HGD)*

*Adenocarcinoma
(EAC)*


Progression in LGD over time



Number at risk at time (years)	1	2	3	4	5
LGD	49	33	27	21	16
IND	30	19	16	12	9
NDBO	137	125	104	75	59

Surveillance flow chart for dysplastic BE

Low overall incidence of EAC
Large screening base
(1 - 2% of the general population)



Barrett mucosa: histopathological assessment

Grading dysplasia according to mucosal features

- Surface maturation (compared to the underlying glands)
 - Architecture of the glands
 - Cytologic features
 - Inflammation and erosions/ulcers
- * Biopsy taken from oesophagus – Contain compatible endoscopic features of Barrett – Intestinal metaplasia is found

Barrett mucosa: histopathological assessment

Amongst the most common types of biopsies encountered in daily practice are esophageal biopsies to evaluate for Barrett esophagus

Difficulties in evaluation include:


- ◇ Duplicated muscularis mucosae in endoscopic mucosal resection (EMR)
- ◇ Distinguishing reactive changes from dysplastic ones
- ◇ Identifying intestinal metaplasia on H-E slides

LGD criteria

Derivation set definition	Validation set definition	Weighted kappa Derivation/Validation set	P-value
Loss of surface maturation	On low power, no maturation of the epithelium is seen from the proliferation zone until the surface	0.27/0.55	<0.001
Clonal step	Abrupt transition of normal epithelium next to dysplastic epithelium	0.05/0.36	0.193
Loss of polarity	More than 45 degrees of deviation of the longitudinal nuclear axis	0.06/0.29	0.001
Mucin depletion	On high power, almost total to total disappearance of mucus from the surface columnar cells, dystrophic goblet cells* can be permitted	0.11/0.51	<0.001
Stratification of nuclei	Piling of nuclei with minimum of 2 nuclei on top of each; the nuclei do not overlap	0.04/0.29	<0.001
Nuclear enlargement	Nuclear size at least 2x as large as nuclei of the normal columnar epithelium	0.07/0.41	<0.001
Form of nuclei	Elongated (pencil shaped) or round-oval nuclei	0.02/0.13	0.034
Nuclear pleomorphism	Fluctuation of size and form of nuclei compared to nearby normal nuclei of the surface epithelium	0.13/0.36	0.001
Hyperchromasia	Nuclei with a darker hue in comparison to the nuclei of normal columnar epithelium, nucleolus is often not recognizable anymore	0.18/0.25	0.329
Prominent nucleolus	Multiple clearly enlarged nucleoli (macronucleoli)	-0.10/0.16	<0.001
Increase in apoptosis	More than 3 crypts in a hundred crypts with nuclear- or necrotic debris	0.03/0.13	0.154
Increase in mitoses	One or more mitoses at the surface or in the neck of the crypts	0.13/0.48	<0.001

Barrett mucosa: histopathological assessment



Foveolar Epithelium



Intestinal metaplasia




Barrett mucosa: histopathological assessment




Barrett mucosa: histopathological assessment

Barrett oesophagus: **Negative** for dysplasia




Barrett mucosa: histopathological assessment

Barrett oesophagus: **Indefinite** for dysplasia




- Inflammation
- Tangential embedding-cutting
- Hypermucinous features



Offer an explanation


Barrett mucosa: histopathological assessment

Barrett oesophagus: **Low Grade** Dysplasia (LGD)



Barrett mucosa: histopathological assessment


Barrett oesophagus: **High Grade** Dysplasia (HGD)



Barrett mucosa: histopathological assessment


Barrett oesophagus: **Intramucosal** Carcinoma

(invasion through the basement membrane into the lamina propria or muscularis mucosae but not beyond)




Barrett mucosa: histopathological assessment

Barrett oesophagus: **Intramucosal** Carcinoma




Barrett mucosa: histopathological assessment

Using modern techniques, endoscopic treatment for HGD and intramucosal carcinoma has become the standard




Surveillance epidemiology and end results data show that patients with HGD and early carcinomas have the same mortality whether managed endoscopically or surgically



**Endoscopic Mucosal Resection
(EMR)**


Barrett mucosa: histopathological assessment



Lift the mucosa by injecting in the submucosa fluid




This creates an artificial "polyp" that is then resected using a cauterizing snare




Barrett mucosa: histopathological assessment



Barrett mucosa: histopathological assessment





Esophageal Cancer Staging



Histologic assessment

- In the esophagus lesion: double layer of muscularis mucosae








Lym

Keratin



essel invasion

ascular invasion



Histological assessment: Surgical margins



- In positive cases describe t



ICOS

Histological assessment: Surgical margins


- If tumor cells are hard to identify due to cauterization-



if the positive margin shows no cauterization effect → **false positivity should be considered** → deeper cut section should be obtained

Conclusion

- 1 **Macroscopy**
- 2 **Size of the lesion**
- 3 **Differentiation of the tumor**
- 4 **Depth of invasion**
- 5 **Lymphovascular/Venous invasion**
- 6 **Margin status**



Relevant to prognosis
and additional
treatment decisions

Esophagus: ESGE Guideline

- BE with adenocarcinoma:
- No surgical treatment
 - G1-3, m1-3, LVI-, R0
 - G1-2, sm1 ($\leq 500 \mu\text{m}$), LVI-, R0
 - If the horizontal margin is positive or there is piecemeal resection with no other high risk criteria, endoscopic surveillance/re-treatment is recommended rather than surgery
- Treatment:
 - G3sm1
 - G1-2>sm1 ($> 500 \mu\text{m}$)
 - LVI+
 - R1 (vertical)